Aldosterone and the mineralocorticoid receptor in the cerebral circulation and stroke

Experimental and Translational Stroke Medicine

Volumn 4, Issue 1, 2012, Pages

  Dinh, Quynh N ^a   Arumugam, Thiruma V ^b   Young, Morag J ^a   Drummond, Grant R ^a   Sobey, Christopher G ^a   Chrissobolis, Sophocles ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Aldosterone; Mineralocorticoid receptor; Stroke; Vascular remodelling

Indexed keywords

ALDOSTERONE; CAPTOPRIL; EPLERENONE; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; OXPRENOATE POTASSIUM; SPIRONOLACTONE;

BRAIN BLOOD VESSEL; BRAIN CIRCULATION; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CORTICOSTEROID BLOOD LEVEL; HUMAN; HYPERTENSION; IMMUNOCOMPETENT CELL; NONHUMAN; OUTCOME ASSESSMENT; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; VASCULAR DISEASE;

EID: 84872656360     PISSN: None     EISSN: 20407378     Source Type: Journal    
DOI: 10.1186/2040-7378-4-21     Document Type: Review

References (62)

1. Stier CT, Chander PN, Rocha R. Aldosterone as a mediator in cardiovascular injury. Cardiol Rev 2002, 10:97-107. 10.1097/00045415-200203000-00008, 11895576.
2. Herrada AA, Campino C, Amador CA, Michea LF, Fardella CE, Kalergis AM. Aldosterone as a modulator of immunity: implications in the organ damage. J Hypertens 2011, 29:1684-1692. 10.1097/HJH.0b013e32834a4c75, 21826023.
3. Han F, Ozawa H, Matsuda KI, Lu H, De Kloet ER, Kawata M. Changes in the expression of corticotrophin-releasing hormone, mineralocorticoid receptor and glucocorticoid receptor mRNAs in the hypothalamic paraventricular nucleus induced by fornix transection and adrenalectomy. J Neuroendocrinol 2007, 19:229-238. 10.1111/j.1365-2826.2006.01519.x, 17244200.
4. Schiffrin EL. Effects of aldosterone on the vasculature. Hypertension 2006, 47:312-318. 10.1161/01.HYP.0000201443.63240.a7, 16432039.
5. Takeda Y, Miyamori I, Yoneda T, Iki K, Hatakeyama H, Blair IA, Hsieh FY, Takeda R. Production of aldosterone in isolated rat blood vessels. Hypertension 1995, 25:170-173. 10.1161/01.HYP.25.2.170, 7843766.
6. Rajagopalan S, Duquaine D, King S, Pitt B, Patel P. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 2002, 105:2212-2216. 10.1161/01.CIR.0000015854.60710.10, 11994257.
7. Silvestre JS, Robert V, Heymes C, Aupetit-Faisant B, Mouas C, Moalic JM, Swynghedauw B, Delcayre C. Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J Biol Chem 1998, 273:4883-4891. 10.1074/jbc.273.9.4883, 9478930.
8. Milik E, Szczepanska-Sadowska E, Maslinski W, Cudnoch-Jedrzejewska A. Enhanced expression of mineralocorticoid receptors in the heart after the myocardial infarct in rats. J Physiol Pharmacol 2007, 58:745-755.
9. Fuller PJ, Yao Y, Yang J, Young MJ. Mechanisms of ligand specificity of the mineralocorticoid receptor. J Endocrinol 2012, 213:15-24. 10.1530/JOE-11-0372, 22159507.
10. Gomez-Sanchez EP. Mineralocorticoid receptors in the brain and cardiovascular regulation: minority rule?. Trends Endocrinol Metab 2011, 22:179-187. 10.1016/j.tem.2011.02.001, 3140534, 21429762.
11. McCurley A, Jaffe IZ. Mineralocorticoid receptors in vascular function and disease. Mol Cell Endocrinol 2012, 350:256-265. 10.1016/j.mce.2011.06.014, 21723914.
12. Kornel L. Colocalization of 11 beta-hydroxysteroid dehydrogenase and mineralocorticoid receptors in cultured vascular smooth muscle cells. Am J Hypertens 1994, 7:100-103.
13. Fuller PJ, Young MJ. Mechanisms of mineralocorticoid action. Hypertension 2005, 46:1227-1235. 10.1161/01.HYP.0000193502.77417.17, 16286565.
14. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005, 45:1243-1248. 10.1016/j.jacc.2005.01.015, 15837256.
15. Moskowitz MA, Lo EH, Iadecola C. The science of stroke: mechanisms in search of treatments. Neuron 2010, 67:181-198. 10.1016/j.neuron.2010.07.002, 2957363, 20670828.
16. Lim HY, Muller N, Herold MJ, van den Brandt J, Reichardt HM. Glucocorticoids exert opposing effects on macrophage function dependent on their concentration. Immunology 2007, 122:47-53. 10.1111/j.1365-2567.2007.02611.x, 2265978, 17451463.
17. Boldyreff B, Wehling M. Aldosterone: refreshing a slow hormone by swift action. News Physiol Sci 2004, 19:97-100.
18. Gros R, Ding Q, Sklar LA, Prossnitz EE, Arterburn JB, Chorazyczewski J, Feldman RD. GPR30 Expression Is Required for the Mineralocorticoid Receptor-Independent Rapid Vascular Effects of Aldosterone. Hypertension 2011, 57:442-451. 10.1161/HYPERTENSIONAHA.110.161653, 21242460.
19. Lemarie CA, Paradis P, Schiffrin EL. New insights on signaling cascades induced by cross-talk between angiotensin II and aldosterone. J Mol Med 2008, 86:673-678. 10.1007/s00109-008-0323-5, 18368382.
20. Menard J. The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Mol Cell Endocrinol 2004, 217:45-52. 10.1016/j.mce.2003.10.008, 15134800.
21. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998, 31:451-458. 10.1161/01.HYP.31.1.451, 9453344.
22. Rocha R, Stier CT. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab 2001, 12:308-314. 10.1016/S1043-2760(01)00432-5, 11504670.
23. Dorrance AM, Osborn HL, Grekin R, Webb RC. Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats. Am J Physiol Regul Integr Comp Physiol 2001, 281:R944-950.
24. Iwanami J, Mogi M, Okamoto S, Gao XY, Li JM, Min LJ, Ide A, Tsukuda K, Iwai M, Horiuchi M. Pretreatment with eplerenone reduces stroke volume in mouse middle cerebral artery occlusion model. Eur J Pharmacol 2007, 566:153-159. 10.1016/j.ejphar.2007.03.043, 17475237.
25. Frieler RA, Meng H, Duan SZ, Berger S, Schutz G, He Y, Xi G, Wang MM, Mortensen RM. Myeloid-specific deletion of the mineralocorticoid receptor reduces infarct volume and alters inflammation during cerebral ischemia. Stroke 2011, 42:179-185. 10.1161/STROKEAHA.110.598441, 3042719, 21106954.
26. Usher MG, Duan SZ, Ivaschenko CY, Frieler RA, Berger S, Schutz G, Lumeng CN, Mortensen RM. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest 2010, 120:3350-3364. 10.1172/JCI41080, 2929712, 20697155.
27. Pello OM, Silvestre C, De Pizzol M, Andres V. A glimpse on the phenomenon of macrophage polarization during atherosclerosis. Immunobiology 2011, 216:1172-1176. 10.1016/j.imbio.2011.05.010, 21802768.
28. Dorrance AM, Rupp NC, Nogueira EF. Mineralocorticoid receptor activation causes cerebral vessel remodeling and exacerbates the damage caused by cerebral ischemia. Hypertension 2006, 47:590-555. 10.1161/01.HYP.0000196945.73586.0d, 16365191.
29. Meier P, Maillard M, Burnier M. The future of angiotensin II inhibition in cardiovascular medicine. Curr Drug Targets Cardiovasc Haematol Disord 2005, 5:15-30. 10.2174/1568006053004994, 15720221.
30. Hankey GJ. Angiotensin-converting enzyme inhibitors for stroke prevention: is there HOPE for PROGRESS After LIFE?. Stroke 2003, 34:354-356. 10.1161/01.STR.0000054261.97525.4B, 12574534.
31. MacLeod AB, Vasdev S, Smeda JS. The role of blood pressure and aldosterone in the production of hemorrhagic stroke in captopril-treated hypertensive rats. Stroke 1997, 28:1821-1828. discussion 1829, 10.1161/01.STR.28.9.1821, 9303031.
32. Smeda J, Vasdev S, King SR. Effect of poststroke captopril treatment on mortality associated with hemorrhagic stroke in stroke-prone rats. J Pharmacol Exp Ther 1999, 291:569-575.
33. Smeda JS, Daneshtalab N. The effects of poststroke captopril and losartan treatment on cerebral blood flow autoregulation in SHRsp with hemorrhagic stroke. J Cereb Blood Flow Metab 2011, 31:476-485. 10.1038/jcbfm.2010.110, 3049503, 20648036.
34. Takeda Y, Miyamori I, Inaba S, Furukawa K, Hatakeyama H, Yoneda T, Mabuchi H, Takeda R. Vascular aldosterone in genetically hypertensive rats. Hypertension 1997, 29:45-48. 10.1161/01.HYP.29.1.45, 9039078.
35. Bomback AS, Toto R. Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination. Am J Hypertens 2009, 22:1032-1040. 10.1038/ajh.2009.138, 19661925.
36. Hillaert MA, Lentjes EG, Kemperman H, van der Graaf Y, Nathoe HM, Beygui F, Montalescot G, Doevendans PA, Wassink AM, van Belle E. Aldosterone, atherosclerosis and vascular events in patients with stable coronary artery disease. Int J Cardiol 2012, The PMID is 22727970.
37. Litchfield WR, Anderson BF, Weiss RJ, Lifton RP, Dluhy RG. Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism. Hypertension 1998, 31:445-450. 10.1161/01.HYP.31.1.445, 9453343.
38. Vyssoulis GP, Karpanou EA, Tzamou VE, Kyvelou SM, Michaelidis AP, Gialernios TP, Cokkinos DV, Stefanadis CI. Aldosterone levels and stroke incidence in essential hypertensive patients. Int J Cardiol 2009, 144:171-172.
39. Osmond JM, Rigsby CS, Dorrance AM. Is the mineralocorticoid receptor a potential target for stroke prevention?. Clin Sci (Lond) 2008, 114:37-47.
40. Satoh M, Kikuya M, Ohkubo T, Mori T, Metoki H, Hara A, Utsugi MT, Hashimoto T, Hirose T, Obara T, et al. Aldosterone-to-renin ratio as a predictor of stroke under conditions of high sodium intake: the Ohasama study. Am J Hypertens 2012, 25:777-783. 10.1038/ajh.2012.33, 22476023.
41. Olivieri O, Pizzolo F, Ciacciarelli A, Corrocher R, Signorelli D, Falcone S, Blengio GS. Menopause not aldosterone-to-renin ratio predicts blood pressure response to a mineralocorticoid receptor antagonist in primary care hypertensive patients. Am J Hypertens 2008, 21:976-982. 10.1038/ajh.2008.234, 18600211.
42. Miller JA, Anacta LA, Cattran DC. Impact of gender on the renal response to angiotensin II. Kidney Int 1999, 55:278-285. 10.1046/j.1523-1755.1999.00260.x, 9893137.
43. Schunkert H, Danser AH, Hense HW, Derkx FH, Kurzinger S, Riegger GA. Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women. Circulation 1997, 95:39-45. 10.1161/01.CIR.95.1.39, 8994414.
44. Danser AH, Derkx FH, Schalekamp MA, Hense HW, Riegger GA, Schunkert H. Determinants of interindividual variation of renin and prorenin concentrations: evidence for a sexual dimorphism of (pro)renin levels in humans. J Hypertens 1998, 16:853-862. 10.1097/00004872-199816060-00017, 9663926.
45. Rigsby CS, Burch AE, Ogbi S, Pollock DM, Dorrance AM. Intact female stroke-prone hypertensive rats lack responsiveness to mineralocorticoid receptor antagonists. Am J Physiol Regul Integr Comp Physiol 2007, 293:R1754-1763. 10.1152/ajpregu.00145.2007, 2804103, 17670862.
46. Rahmouni K, Barthelmebs M, Grima M, Imbs JL, De Jong W. Cardiovascular and renal effects of central administration of a mineralocorticoid receptor antagonist in conscious female rats. Eur J Pharmacol 1999, 385:199-202. 10.1016/S0014-2999(99)00705-0, 10607876.
47. Lai M, Horsburgh K, Bae SE, Carter RN, Stenvers DJ, Fowler JH, Yau JL, Gomez-Sanchez CE, Holmes MC, Kenyon CJ, et al. Forebrain mineralocorticoid receptor overexpression enhances memory, reduces anxiety and attenuates neuronal loss in cerebral ischaemia. Eur J Neurosci 2007, 25:1832-1842. 10.1111/j.1460-9568.2007.05427.x, 17432969.
48. Macleod MR, Johansson IM, Soderstrom I, Lai M, Gido G, Wieloch T, Seckl JR, Olsson T. Mineralocorticoid receptor expression and increased survival following neuronal injury. Eur J Neurosci 2003, 17:1549-1555. 10.1046/j.1460-9568.2003.02587.x, 12752372.
49. Lai M, Bae SE, Bell JE, Seckl JR, Macleod MR. Mineralocorticoid receptor mRNA expression is increased in human hippocampus following brief cerebral ischaemia. Neuropathol Appl Neurobiol 2009, 35:156-164. 10.1111/j.1365-2990.2008.00980.x, 19284477.
50. Hwang IK, Yoo KY, Nam YS, Choi JH, Lee IS, Kwon YG, Kang TC, Kim YS, Won MH. Mineralocorticoid and glucocorticoid receptor expressions in astrocytes and microglia in the gerbil hippocampal CA1 region after ischemic insult. Neurosci Res 2006, 54:319-327. 10.1016/j.neures.2005.12.012, 16473422.
51. Crochemore C, Lu J, Wu Y, Liposits Z, Sousa N, Holsboer F, Almeida OF. Direct targeting of hippocampal neurons for apoptosis by glucocorticoids is reversible by mineralocorticoid receptor activation. Mol Psychiatry 2005, 10:790-798. 10.1038/sj.mp.4001679, 15940303.
52. Almeida OF, Conde GL, Crochemore C, Demeneix BA, Fischer D, Hassan AH, Meyer M, Holsboer F, Michaelidis TM. Subtle shifts in the ratio between pro- and antiapoptotic molecules after activation of corticosteroid receptors decide neuronal fate. FASEB J 2000, 14:779-790.
53. Oyamada N, Sone M, Miyashita K, Park K, Taura D, Inuzuka M, Sonoyama T, Tsujimoto H, Fukunaga Y, Tamura N, et al. The role of mineralocorticoid receptor expression in brain remodeling after cerebral ischemia. Endocrinology 2008, 149:3764-3777. 10.1210/en.2007-1770, 2488212, 18436714.
54. Chrissobolis S, Faraci FM. The role of oxidative stress and NADPH oxidase in cerebrovascular disease. Trends Mol Med 2008, 14:495-502. 10.1016/j.molmed.2008.09.003, 3140460, 18929509.
55. Cachofeiro V, Miana M, de Las Heras N, Martin-Fernandez B, Ballesteros S, Fernandez-Tresguerres J, Lahera V. Aldosterone and the vascular system. J Steroid Biochem Mol Biol 2008, 109:331-335. 10.1016/j.jsbmb.2008.03.005, 18400490.
56. Lacolley P, Labat C, Pujol A, Delcayre C, Benetos A, Safar M. Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone. Circulation 2002, 106:2848-2853. 10.1161/01.CIR.0000039328.33137.6C, 12451013.
57. McCurley A, Pires PW, Bender SB, Aronovitz M, Zhao MJ, Metzger D, Chambon P, Hill MA, Dorrance AM, Mendelsohn ME, Jaffe IZ. Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat Med 2012, The PMID is 22922412.
58. Rigsby CS, Pollock DM, Dorrance AM. Spironolactone improves structure and increases tone in the cerebral vasculature of male spontaneously hypertensive stroke-prone rats. Microvasc Res 2007, 73:198-205. 10.1016/j.mvr.2006.12.001, 1913209, 17250855.
59. Rigsby CS, Ergul A, Portik Dobos V, Pollock DM, Dorrance AM. Effects of spironolactone on cerebral vessel structure in rats with sustained hypertension. Am J Hypertens 2011, 24:708-715. 10.1038/ajh.2011.20, 21350432.
60. Herrada AA, Contreras FJ, Marini NP, Amador CA, Gonzalez PA, Cortes CM, Riedel CA, Carvajal CA, Figueroa F, Michea LF, et al. Aldosterone promotes autoimmune damage by enhancing Th17-mediated immunity. J Immunol 2010, 184:191-202. 10.4049/jimmunol.0802886, 19949098.
61. Caprio M, Newfell BG, la Sala A, Baur W, Fabbri A, Rosano G, Mendelsohn ME, Jaffe IZ. Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ Res 2008, 102:1359-1367. 10.1161/CIRCRESAHA.108.174235, 2597516, 18467630.
62. Kasal DA, Barhoumi T, Li MW, Yamamoto N, Zdanovich E, Rehman A, Neves MF, Laurant P, Paradis P, Schiffrin EL. T regulatory lymphocytes prevent aldosterone-induced vascular injury. Hypertension 2012, 59:324-330. 10.1161/HYPERTENSIONAHA.111.181123, 22146512.